Back to top
more

Cellebrite DI Ltd. (CLBT)

(Real Time Quote from BATS)

$12.54 USD

12.54
13,205

+0.14 (1.13%)

Updated Aug 6, 2024 09:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CLBT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Cellebrite DI Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 303 184 182 1 0
Receivables 77 79 68 0 0
Notes Receivable 0 0 0 0 0
Inventories 10 10 7 0 0
Other Current Assets 32 23 18 0 0
Total Current Assets 422 296 273 2 0
Net Property & Equipment 16 17 17 0 0
Investments & Advances 29 22 0 600 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 7 13 10 0 0
Intangibles 37 38 38 0 0
Deposits & Other Assets 7 2 2 0 0
Total Assets 533 403 340 602 0
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 53 50 64 0 0
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 196 153 123 0 0
Total Current Liabilities 254 208 187 0 0
Mortgages 0 0 0 0 0
Deferred Taxes/Income 47 42 36 21 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 189 69 190 576 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 499 329 413 597 0
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus -85 -126 -153 5 0
Retained Earnings 118 199 78 0 0
Other Equity 1 0 1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 34 74 -73 5 0
Total Liabilities & Shareholder's Equity 533 403 340 602 0
Total Common Equity 34 74 -73 5 0
Shares Outstanding 188.50 189.60 187.10 17.40 NA
Book Value Per Share 0.18 0.39 -0.39 0.29 0.00

Fiscal Year End for Cellebrite DI Ltd falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 277 303 264 237
Receivables NA 62 77 70 61
Notes Receivable NA 0 0 0 0
Inventories NA 9 10 11 11
Other Current Assets NA 31 32 30 28
Total Current Assets NA 378 422 374 337
Net Property & Equipment NA 16 16 15 16
Investments & Advances NA 71 29 19 7
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 8 7 10 12
Intangibles NA 37 37 38 36
Deposits & Other Assets NA 7 7 8 3
Total Assets NA 529 533 477 426
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 44 53 51 41
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 186 196 171 159
Total Current Liabilities NA 235 254 227 205
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 42 47 48 47
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 189 157 148
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 556 499 439 408
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA -75 -85 -95 -108
Retained Earnings NA 47 118 133 126
Other Equity NA 1 1 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -27 34 38 18
Total Liabilities & Shareholder's Equity NA 529 533 477 426
Total Common Equity 0 -27 34 38 18
Shares Outstanding 205.90 205.30 188.50 194.60 194.60
Book Value Per Share 0.00 -0.13 0.18 0.19 0.09